These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 34985992)

  • 1. Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies.
    Passaro A; Brahmer J; Antonia S; Mok T; Peters S
    J Clin Oncol; 2022 Feb; 40(6):598-610. PubMed ID: 34985992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The combination of immune checkpoint inhibitors and chemotherapy in advanced non-small-cell lung cancer: the rational choice.
    Zouein J; Haddad FG; Eid R; Kourie HR
    Immunotherapy; 2022 Feb; 14(2):155-167. PubMed ID: 34865502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pan-Cancer Analysis Identifies Liver Metastases as Negative Predictive Factor for Immune Checkpoint Inhibitors Treatment Outcome.
    Chen XJ; Ren A; Zheng L; Zheng ED; Jiang T
    Front Immunol; 2021; 12():651086. PubMed ID: 34248939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment.
    Song Y; Fu Y; Xie Q; Zhu B; Wang J; Zhang B
    Front Immunol; 2020; 11():1956. PubMed ID: 32983126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cutting-edge progress of immune-checkpoint blockade in lung cancer.
    Zhou F; Qiao M; Zhou C
    Cell Mol Immunol; 2021 Feb; 18(2):279-293. PubMed ID: 33177696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer.
    Komiya K; Nakamura T; Abe T; Ogusu S; Nakashima C; Takahashi K; Kimura S; Sueoka-Aragane N
    Thorac Cancer; 2019 Sep; 10(9):1798-1804. PubMed ID: 31328416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint inhibitors rechallenge in non-small cell lung cancer: Current evidence and future directions.
    Gang X; Yan J; Li X; Shi S; Xu L; Liu R; Cai L; Li H; Zhao M
    Cancer Lett; 2024 Nov; 604():217241. PubMed ID: 39260670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular dynamics of tumor microenvironment driving immunotherapy resistance in non-small-cell lung carcinoma.
    Huang S; Chung JY; Li C; Wu Y; Qiao G; To KF; Tang PM
    Cancer Lett; 2024 Nov; 604():217272. PubMed ID: 39326553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Advances in Hyperprogressive Disease in Patients 
with Advanced Non-small Cell Lung Cancer Treated with Immunotherapy].
    Yao S; Shi K; Zhang Y
    Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):271-278. PubMed ID: 33910275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Current Landscape of Immune Checkpoint Blockade in Metastatic Lung Squamous Cell Carcinoma.
    Yuan H; Liu J; Zhang J
    Molecules; 2021 Mar; 26(5):. PubMed ID: 33807509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immune-related Adverse Events Induced by ICIs in Advanced NSCLC:
A Meta-analysis and Systematic Review].
    Qin Q; Wang J; Wang H
    Zhongguo Fei Ai Za Zhi; 2020 Sep; 23(9):772-791. PubMed ID: 32752580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy.
    Gataa I; Mezquita L; Rossoni C; Auclin E; Kossai M; Aboubakar F; Le Moulec S; Massé J; Masson M; Radosevic-Robin N; Alemany P; Rouanne M; Bluthgen V; Hendriks L; Caramella C; Gazzah A; Planchard D; Pignon JP; Besse B; Adam J
    Eur J Cancer; 2021 Mar; 145():221-229. PubMed ID: 33516050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or 
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].
    Li H; Qin N; Yu M; Ma L; Wu Y; Zhang H; Zhang X; Li X; Wang J
    Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):161-166. PubMed ID: 33819965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging Blood-Based Biomarkers for Predicting Response to Checkpoint Immunotherapy in Non-Small-Cell Lung Cancer.
    Li S; Zhang C; Pang G; Wang P
    Front Immunol; 2020; 11():603157. PubMed ID: 33178229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments.
    Zheng MM; Tu HY; Yang JJ; Zhang XC; Zhou Q; Xu CR; Jiang BY; Yang XN; Yang XR; Deng JY; Yang MY; Xu BF; Chen XM; Li YS; Wu YL
    Eur J Cancer; 2021 Jun; 150():23-30. PubMed ID: 33882375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer.
    Tfayli A; Al Assaad M; Fakhri G; Akel R; Atwi H; Ghanem H; El Karak F; Farhat F; Al Rabi K; Sfeir P; Youssef P; Mansour Z; Assi H; Haidar M; Abi Ghanem A; Khalifeh I; Boulos F; Mahfouz R; Youssef B; Zeidan Y; Bejjany R; Khuri F
    Cancer Med; 2020 Nov; 9(22):8406-8411. PubMed ID: 32991781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New immunotherapeutic drugs in advanced non-small cell lung cancer (NSCLC): from preclinical to phase I clinical trials.
    Rocco D; Gregorc V; Della Gravara L; Lazzari C; Palazzolo G; Gridelli C
    Expert Opin Investig Drugs; 2020 Sep; 29(9):1005-1023. PubMed ID: 32643447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies to overcome resistance to immune checkpoint blockade in lung cancer.
    Attili I; Tarantino P; Passaro A; Stati V; Curigliano G; de Marinis F
    Lung Cancer; 2021 Apr; 154():151-160. PubMed ID: 33684660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapy.
    Lefebvre C; Martin E; Hendriks LEL; Veillon R; Puisset F; Mezquita L; Ferrara R; Sabatier M; Filleron T; Dingemans AC; Besse B; Raherisson C; Mazières J
    Respir Med Res; 2020 Nov; 78():100788. PubMed ID: 32980653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Advances in Pseudoprogression of Immune Checkpoint Inhibitors 
in Non-small Cell Lung Cancer].
    Tong Y; Long Y; Zhang F; Li J
    Zhongguo Fei Ai Za Zhi; 2024 Apr; 27(4):306-320. PubMed ID: 38769834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.